- Wednesday, 20 May 2015
- Olympic gold medalist Jackie Joyner-Kersee teams up with AstraZeneca to raise awareness about opioid-induced constipation AstraZeneca and Daiichi Sankyo, Inc. today announced that they have partnered with six-time Olympic medalist Jackie Joyner-Kersee to increase awareness of opioid-induced constipation (OIC).
- Saturday, 16 May 2015
- MOVANTIK™ (naloxegol) safety analyses of opioid-induced constipation patients 65 and older with chronic non-cancer pain Further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies presented today at Digestive Disease Week (DDW) 2015 in Washington, D.C. showed that MOVANTIK™ (naloxegol) had a similar incidence of adverse events (AEs) among elderly patients as compared to placebo or usual care. The study evaluated the effects of daily oral administration of MOVANTIK 12.5 mg or 25 mg vs placebo among outpatients 65 years and older with opioid-induced constipation (OIC) and chronic non-cancer pain.
- Wednesday, 13 May 2015
- AstraZeneca to update on progress with immuno-oncology pipeline and combination treatments at ASCO 2015 AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2015. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
- Wednesday, 29 April 2015
- US FDA grants priority review for potential new indication for BRILINTA AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plus low dose aspirin, compared to placebo plus low dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrollment. The Prescription Drug User Fee Act goal date will be in the third quarter of 2015.
- Monday, 27 April 2015
- New initiative to get heart, stroke treatment guidelines to patients faster The American Heart Association is a leader in developing science-based treatment guidelines known to improve outcomes for heart disease and stroke patients. But getting those guidelines consistently used in patient care can often take years. That’s why the association is launching a new initiative that will not only speed up the process for developing guidelines, but also help doctors know about and use them sooner and more often.
- Friday, 24 April 2015
- AstraZeneca PLC first quarter results 2015 Visit our global site to view full details of the event.
- Tuesday, 31 March 2015
- MOVANTIK™ (naloxegol) tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain launched in the US AstraZeneca announced today that MOVANTIK™ (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
- Monday, 30 March 2015
- BRILINTA receives US FDA approval for new administration option AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow BRILINTA 90 mg tablets whole. Unlike other P2Y12 inhibitors, BRILINTA has FDA approval to be crushed and administered in water by swallowing or via nasogastric tube.
- Wednesday, 18 March 2015
- AstraZeneca announces positive Phase III top-line results for PT003 from the PINNACLE 1 and PINNACLE 2 studies in COPD AstraZeneca today announced positive top-line results from the Phase III PINNACLE program, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Saturday, 14 March 2015
- PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack AstraZeneca today announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial that investigated BRILINTA® (ticagrelor) tablets plus low dose aspirin, compared to placebo plus low dose aspirin, for chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrollment.
These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.
View information on AstraZeneca products, including their current US Prescribing Information.